Population Pharmacokinetics and Exposure–Response with Teclistamab in Patients With Relapsed/Refractory Multiple Myeloma: Results From MajesTEC-1Xin Miao, Suzette Girgis, Arnob Banerjee et al.|Targeted Oncology|2023Cited by 46
Teclistamab: Mechanism of action, clinical, and translational scienceYue Guo, Danièle Ouellet, Natalia A. Quijano Cardé et al.|Clinical and Translational Science|2024Cited by 29
Evaluating drug interaction potential from cytokine release syndrome using a physiologically based pharmacokinetic model: A case study of teclistamabMarie‐Emilie Willemin, Suzette Girgis, Shun Xin Wang Lin et al.|CPT Pharmacometrics & Systems Pharmacology|2024Cited by 6
Teclistamab Population Pharmacokinetics and Exposure-Response Relationship Support 1.5 Mg/Kg Dose Regimen in Relapsed/Refractory Multiple MyelomaXin Miao, Honghui Zhou, Liviawati S. Wu et al.|Blood|2022Cited by 5
Drug Interaction Potential As a Result of Cytokine Release Syndrome Using a Physiologically Based Pharmacokinetic Model: Case Study of TeclistamabMarie‐Emilie Willemin, Suzette Girgis, Loeckie De Zwart et al.|Blood|2022Cited by 2